ClinicalTrials.gg
Active, not recruitingNCT07010471EMERALDUpdated Aug 4, 2026

A Clinical Trial for Participants With DEE to Assess Efficacy, Safety, Tolerability, and PK of Relutrigine

A Phase 3 interventional study of 1.0mg/kg/day PRAX-562 and 1.5mg/kg/day PRAX-562 in Developmental and Epileptic Encephalopathy 1, sponsored by Praxis Precision Medicines. Active, not recruiting at 11 sites in 3 countries. Open to participants aged 2 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-08-04.

Sponsored by Praxis Precision Medicines · Phase 3, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
160
Allocation
Randomized
Ages
2 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 793 studies in Epilepsy with a site in United States — 159 open to participants now, 194 under way, 17 of them phase 3. Epilepsy · United States.

Planned enrollment
124th of 588
160 · median 40
Started
2025
with 35 others
Phase 3
126 of 793
10 open now
Primary completion
2026-12
later than 43 of 191 live
Registered
741st of 793
by date

Among the 793 studies in Epilepsy with a site in United States, this one is the 124th largest by planned enrollment of the 588 interventional ones that give a count, is one of 36 that started in 2025, is one of 126 in phase 3, reaches primary completion later than 43 of the 191 other live ones, and was the 741st registered.

Epilepsy

1,850 studies on the registry are indexed under Epilepsy; 418 are open to participants now.

Browse Epilepsy studies →

Open to participants now

159 of the 793 studies in Epilepsy with a site in United States are open now. Recruiting first, the newest first:

154 more — sign in →

All 159 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 284 Epilepsy studies recruiting now, 113 (40%) set no upper age limit and 148 (52%) stop at 75 or younger; 138 take children under 18; 54 take healthy volunteers.

This study: 2 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 793 studies in Epilepsy with a site in United States, or all of them as a file.
02

Study summary

A Phase 3, Randomized, Multi-Center, Double-Blind, Placebo-Controlled Clinical Trial to Evaluate the Efficacy, Safety, Tolerability, and Pharmacokinetics of Relutrigine in Participants with Developmental and Epileptic Encephalopathies Followed by an Open-Label Extension

03

Conditions studied

  • Developmental and Epileptic Encephalopathy 1

Browse trials for

Keywords

  • DEE
  • Developmental and Epileptic Encephalopathy
  • epilepsy
04

Who can participate

Ages eligible
2 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Has a documented diagnosis of a developmental and epileptic encephalopathy.
  • Onset of seizures \<12 years old.
  • Has a weight >7 kg at the time of signing consent/assent.

Exclusion criteria

Exclusion Criteria:

  • Has a history of left bundle branch block, arrhythmias, Brugada syndrome, congenital heart disease, familial short syndrome, or family history of sudden death or ventricular arrhythmias, including idiopathic ventricular fibrillation.
  • Had 2 or more episodes of convulsive status epilepticus requiring hospitalization and intubation in the 6 months prior to Screening.
  • Has an abnormal reading, including a QT interval corrected for heart rate using Bazett's method (QTcB) \<350 and >450 ms (males), or \<360 and >460 ms (females) at Screening and/or on Day 1.
  • Any nerve stimulation must have been placed at least 3 months prior to Screening with at least 1 month of stable settings prior to Screening.
  • Has received any other experimental or drug, device, or other therapy within 30 days or 5 half-lives (whichever is longer) prior to Screening, including any prior use of gene therapy.
  • Is currently pregnant or breastfeeding or is planning to become pregnant during the clinical trial or within 5 half-lives of the last study drug dose.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Sequential assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
160 participants (estimated)

Study arms

  • Experimental
    Part A: Double-Blind Treatment Period

    Eligible participants will be randomly assigned in a double-blind manner and a 1:1 ratio to receive 1.0mg-1.5mg/kg relutrigine or placebo once daily orally or gastronomy/jejunostomy for 16 weeks

    Drug: 1.0mg/kg/day PRAX-562 · Drug: 1.5mg/kg/day PRAX-562

  • Placebo comparator
    Part A: Double-Blind Treatment Period (Placebo)

    Eligible participants will be randomly assigned in a double-blind manner and a 1:1 ratio to receive 1.0mg-1.5mg/kg relutrigine or placebo once daily orally or gastronomy/jejunostomy for 16 weeks

    Drug: Placebo

  • Experimental
    Part B: Open-Label Extension Treatment Period

    Participants from Part A will have the option to rollover to Part B to receive 1.0mg-1.5mg/kg of relutrigine once daily orally or gastronomy/jejunostomy for 32 weeks

    Drug: 1.0mg/kg/day PRAX-562 · Drug: 1.5mg/kg/day PRAX-562

Interventions

  • Drug1.0mg/kg/day PRAX-562

    Once daily orally or gastronomy/jejunostomy

    Also known as: relutrigine

  • Drug1.5mg/kg/day PRAX-562

    Once daily orally or gastronomy/jejunostomy

  • DrugPlacebo

    Once daily orally or gastronomy/jejunostomy

06

What researchers measure

Primary outcomes

  1. To assess the effect of relutrigine on seizure frequency in participants with DEEs compared to placebo

    Change from baseline in monthly motor seizure frequency

    Time frame: 16 weeks

Secondary outcomes

  1. Achieve >50% reduction in monthly seizure frequency from baseline

    Proportion of patients achieving \>50% reduction in monthly seizure frequency from baseline

    Time frame: 16 weeks

  2. Change in seizure-free days

    Change in seizure-free days from baseline

    Time frame: 16 weeks

  3. Clinical Global Impression-Severity questionnaire

    CGI-S at baseline after 16 weeks

    Time frame: 16 weeks

  4. Clinical Global Impression-Improvement questionnaire

    CGI-I subdomains scores after 16 weeks

    Time frame: 16 weeks

  5. Caregiver Global Impression-Severity questionnaire

    CgGI-S at baseline after 16 weeks

    Time frame: 16 weeks

  6. Caregiver Global Impression-Improvement questionnaire

    CgGI-I subdomains scores after 16 weeks

    Time frame: 16 weeks

  7. To evaluate the safety and tolerability of relutrigine in participants with DEEs

    Incidence and severity of TEAEs

    Time frame: 16 weeks

  8. Columbia-Suicide Severity Rating Scale questionnaire

    Incidence of suicidal ideation or behavior as measured by the C-SSRS

    Time frame: 16 weeks

  9. Evaluate the safety and tolerability of relutrigine in participants with DEEs

    Incidence of clinically significant ECG abnormalities

    Time frame: 16 weeks

  10. To evaluate the safety labs and tolerability of relutrigine in participants with DEEs

    The principal investigator (PI) or sub investigator will review the laboratory report and document this review. Any clinically significant adverse changes occurring during the clinical trial will be documented as adverse events.

    Time frame: 16 weeks

  11. To evaluate the change in respiratory rate and tolerability of relutrigine in participants with DEEs

    Change in respiratory rate in breaths per minute

    Time frame: 16 weeks

  12. To evaluate the change in blood pressure and tolerability of relutrigine in participants with DEEs

    Change in blood pressure in mm/Hg

    Time frame: 16 weeks

  13. To evaluate the change in pulse and tolerability of relutrigine in participants with DEEs

    Change in heart rate in beats per minute

    Time frame: 16 weeks

  14. To evaluate the change in body temperature and tolerability of relutrigine in participants with DEEs

    Change in tympanic temperature in Celsius

    Time frame: 16 weeks

07

Study locations

11 sites
  • Praxis Research Site
    La Jolla, California 92037, United States
  • Praxis Research Site
    Gulf Breeze, Florida 32561, United States
  • Praxis Research Site
    Chevy Chase, Maryland 20815, United States
  • Praxis Research Site
    Roseville, Minnesota 55113, United States
  • Praxis Research Site
    Hackensack, New Jersey 07601, United States
  • Praxis Research Site
    Philadelphia, Pennsylvania 19104, United States
  • Praxis Research Site
    Heidelberg, Victoria 3084, Australia
  • Praxis Research Site
    Rio Grande, Do Sul 90610, Brazil
  • Praxis Research Site
    Paraná, 80250, Brazil
  • Praxis Research Site
    Rio de Janeiro, 20231, Brazil
  • Praxis Research Site
    São Paulo, 15090, Brazil
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jul 2025 (actual). Primary completion is estimated for Dec 2026, 17 months after the start.

Of 66 industry-sponsored phase 3 interventional studies under Epilepsy, half reached primary completion within 48 months of starting (the median), counting those still running; a quarter within 30 and three quarters within 70. This study's planned 17 months is below that.

Counting every sponsor, half of 86 studies reached it within 48 months; a quarter within 29 and three quarters within 69.

How these figures are worked out, and which studies are left out of them.

Registered
May 30, 2025
First posted
Jun 8, 2025
StartActual
Jul 9, 2025
Primary completionEst.
Dec 2026
CompletionEst.
Nov 2027
Last update
Aug 4, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 4, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07010471
Lead sponsor
Praxis Precision Medicines
Responsible party
Sponsor
First posted
Jun 8, 2025
Start date
Jul 9, 2025
Primary completion
Dec 2026 (estimated)
Completion
Nov 2027 (estimated)
Last update
Aug 4, 2026

Study contacts

Medical Director
study director · Praxis Precision Medicines

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Jul 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion